Oncolytics Biotech Inc T.ONC

Thanks West ---the Bull Case -Unoteable??

[HCallahann44]

I wonder---I bought another 1000 shares today...but in this market momo always seems to prevail so sava may zoom to 3200 while we languish. Even though the stock drops every day I keep coming back to the following---- 1. Pela is SAFE ---product safety is what tanks most biotechs...our virus has passed that test. We had permission to move to Phase 3 but held off to ID biomarkers...which we have now done with some success. 2. It seems to work with every type of Immunotherapy --and one wonders just how well it would work if the test cases were not previously fried with radiation and chemo. 3. It can be administered by low level medical personnel...its systemic and finds the cancer---maybe the only onco virus that can be administered this way....though there may be one other...but its genetically engineered...I think its safer to stay away from the genetic tampering stuff... 4. We are partnering with a lot of big pharma....some on the yahoo board will write this off...saying ---nah they are just letting ONCY play with their meds. I doubt this is the case...given the risks and liability. These pharmas must have done a ton of DD before agreeing to these trials. 5. Every analyst that has looked at it...in a lot more detail than we have is projecting a price a min of 4x higher than today. 6. Making these other immunotherapy treatments just a fraction more effective translates into big $$$ for the pharmas. 7. Big pharma could pay what is a small amount of money to the pharma...but that could translate to a big pay day for us. 8. Other companies with products that don't appear as versatile as PELA are selling for 10x our current market cap. 8. All of this has to be balanced against a lack of insider buying...a lack of institutional buying...even by institutions whose analysts are saying the stock is a strong buy ----these factors are what keep me up!! And I wonder if the royalty payments are a factor holding back a sale? Does Matt care if he gets a good price for the company if most of his compensation is in the royalty side???

[westcoast1000]

HC, in reply, I think there almost certainly have been low ball buyout offers in the past. Matt is looking for a partner at a reasonable price, who will also carry the financial burden on the Ph 3. For me, the opportunities with CIs and Car-T combos are potentially bigger than the BC prospect. 

[unNoteable]

I agree with your last point west, as cure is infinitely better than better OS. There is always the danger that Bracelet-1 does not show the efficacy and improvement that the all the side trials and theory suggest. As yet we don't have Pela+CPI proof of improved patient outcomes, only hints. It's going to be a wild ride these next 5 months,

[HarryCallahan45]

Unoteable --- you have hit the nail on the head...and likely explained why insider and institutional ownership is so low.  My Biotech analyst friend took a quick look at ONCY....gave us props for safety...but said the action of Pela thus far has been weak....just adding a few months to survivability here and there.  He advised that Oncorus was a better play as their virus is getting

[JohnnyYeg]

You just can't accept being ignored can you Hairy? You come on here and spew your sh*t and people ignore you so you have to create a new profile. I call BS on you, on your imaginary biotech analyst friend, and your baseless statements and accusations.

[HarryCallahan45]

Thanks for the well reasoned rebuttal.  go ahead and block me ---you add zero value here

[fasttrack5]

By by ARRY

[Noteable]

Basic research by anyone would show that Oncorus is a Phase 1 early stage OV company with a intratumorally (IT) administered HSV in melanoma, which is a crowded indication to try to develop an OV candidate. Furthermore, their pipeline is still in the pre-clinical stage with any potential IV administered OV products, which were decided on development in May 2021, using the Coxsckievirus and Seneca

[Noteable]

Also Oncorus is not planning on filing an investigational new drug (IND) application on one of its preclinical candidates ONC-021 (Coxsackie Virus), so that Phase 1 clincal research can be conducted, until H1'2023

[Noteable]

Furthermore, Oncorus does not show how a microencapsulated oncolytic virus (Coxsackie or Seneca virus) administered systemcially would be released at the tumor site if it when such engineered virus would reach the tumor site. There is no mechanism for the release of such virus and no such indication that such a microencapsulated virus could ever be delivered systemically to the tumor and whether